Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Arinia Pharmaceuticals fourth quarter and full year 2024 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Andrea Christopher, Head of Corporate Communication and Investor Relations for Arinia. Thank you. You may begin. Thank you, Operator, and thank you to everyone for joining today's call and webcast. Joining me on the call this morning are Peter Greenleaf, Arania's President and Chief Executive Officer, Joe Miller, Arania's Chief Financial Officer, and Dr. Greg Keenan, Arania's Chief Medical Officer. Today, we will review and discuss Arania's fourth quarter and full year 2024 financial results and provide an update on recent corporate progress, as communicated in the company's press release and annual report, on Form 10K issued this morning. For more information, please refer to ARINIA's filings with the U.S. Securities and Exchange Commission and Canadian Securities Authorities, which are also available on ARINIA's website at ARINIApharma.com. During today's call, ARINIA may make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and actual results may differ materially. For a discussion of factors that could affect Arrhenius' future financial results and business, please refer to the disclosures in Arrhenius' press release, annual report on Form 10-K, and all other filings with the U.S. Securities and Exchange Commission ...